Just like last quarter, the year-over-year changes in Becton, Dickinson's (NYSE:BDX) third fiscal quarter looked outstanding, but that's only because of the addition of revenue from C.R. Bard. Fortunately, management of the medical supply company was nice enough to provide comparable results as if the company owned Bard in the year-ago quarter, which showed BD continued its slow but steady approach while taking advantage of the cost savings from the acquisition.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,